Tolterodine Extended Release Attenuates Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia

Kaplan, Steven A.; Walmsley, Konstantin; Te, Alexis E.

doi:10.1016/j.juro.2008.03.142

Cited by 29 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, several studies have reported that prescribing anti-muscarinic agents to men with LUTS or even BOO does not seem to elevate the risk of AUR [11,40]. The results of several studies support the efficacy and safety of antimuscarinics in treating men with LUTS and OAB [41–44]. For example, Abrams et al [11] reported the efficacy of tolterodine immediate-release in men with both BOO and OAB.…”

Section: Antimuscarinic Agentsmentioning

confidence: 99%

“…In recent years, a number of studies have reported on the combination treatment of alpha receptor antagonists and antimuscarinic agents [12,41–47]. In a 2006 study by Kaplan et al [48] named the TIMES study, tolterodine extend release (ER) and tamsulosin combination treatment resulted in significant improvement in urgency episodes, number of micturitions, nocturia, and IPSS.…”

Section: Combination Treatment: Alpha Receptor Antagonists + Antimuscmentioning

confidence: 99%

See 1 more Smart Citation

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

Lee

2014

Prostate International

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are highly prevalent in older men. The storage subcategory of LUTS is synonymous with overactive bladder (OAB) syndrome, which is an empirical diagnosis. Traditionally, alpha-blockers are widely prescribed to manage the LUTS of BPH, although storage symptoms may persist in many men despite treatment. Therefore, because therapies that target the prostate often fail to alleviate storage symptoms, they may not be the appropriate therapy for OAB. In past years, most physicians appeared to give more weight in elderly men to voiding symptoms than to storage symptoms and to be more concerned with initial treatment with anticholinergics for males with storage symptoms. Considering the recent increase in data on the efficacy and safety of combination treatment with alpha receptor antagonists and antimuscarinic agents, the standard pharmacologic treatment of patients with LUTS combined with OAB should be an alpha receptor antagonist and an antimuscarinic agent. Beta-3 adrenoreceptor agonists may also potentially be useful for the treatment of male LUTS combined with OAB.

show abstract

Section: Antimuscarinic Agentsmentioning

confidence: 99%

Section: Combination Treatment: Alpha Receptor Antagonists + Antimuscmentioning

confidence: 99%

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

Lee

2014

Prostate International

View full text Add to dashboard Cite

show abstract

“…A recent open-label study evaluated the safety and efficacy of extended-release tolterodine in 43 men with lower urinary tract symptoms because of benign prostatic enlargement and in whom -blocker therapy had failed previously [34]. At 6 months the AUA symptom score improved from 17.3 at baseline to 11.2 at 6 months (-6.1, P < 0.001).…”

Section: Urinary Retentionmentioning

confidence: 99%

How to choose the initial drug treatment for overactive bladder

MacDiarmid¹

2008

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

“…Data suggest that antimuscarinic agents are safe and effective in treating storage symptoms in men with LUTS [9][10][11][12][13]. However, there is skepticism regarding their use because of the concern of an increased risk of urinary retention [14].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Tamsulosin With and Without Flavoxate in the Treatment of Symptomatic Benign Prostastic Hypoplasia: A Randomized, Single-Blind Study

Dash¹,

Kumar²,

Pandey³

et al. 2010

UIJ

View full text Add to dashboard Cite

Abbreviations and AcronymsBPH = benign prostatic hyperplasia IPSS = International Prostate Symptom Score LUTS = lower urinary tract symptoms OAB = overactive bladder PSA = prostate-specific antigen PVR = postvoid residual QoL = quality of life Qmax = maximum urinary flow rate. ABSTRACT INTRODUCTION:The purpose of the study was to evaluate the efficacy and safety of tamsulosin plus flavoxate with tamsulosin plus a placebo for the treatment of clinically proven lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). METHODS:The participants were 120 patients with BPH and LUTS who were randomized into 2 equal groups.Group 1 received tamsulosin modified release (0.4 mg) once daily and flavoxate (200 mg) 3 times daily; group 2 received tamsulosin modified release (0.4 mg) once daily and a placebo 3 times daily. All patients took the medications orally for 12 weeks. Patients were evaluated before and after treatment by the total International Prostate Symptoms Score (IPSS), the irritative symptoms, voiding symptoms, and quality of life (QoL) IPSS subscores, maximum urinary flow rate (Qmax), and postvoid residual (PVR) urine volume. Adverse events were also summarized. The t test was used for group comparisons in response to treatment. RESULTS:All patients responded positively to treatment. The group taking tamsulosin plus flavoxate had significant improvement in the mean total IPSS (P < .001), irritative symptom subscore (P < .002), and QoL score (P < .002) when compared with the group taking tamsulosin plus placebo. There was no significant group difference in the mean voiding symptom subscore, Qmax, or PVR volume. Group differences in mean frequency and nocturia at the end of 12 weeks approached statistical significance (P = .05); patients taking tamsulosin plus flavoxate had fewer episodes. There was no significant group difference in urgency. One patient withdrew from each group due to complaints of impotence and ejaculatory dysfunction; all other adverse events were mild and transient. CONCLUSION:Taking a combination of tamsulosin with flavoxate improved IPSS, irritating symptoms, and QoL significantly more than taking the alpha blocker alone. The combined drugs had good safety and can be considered as a therapeutic option for treatment of LUTS associated with BPH. UroToday International Journal ® UI J

show abstract

Tolterodine Extended Release Attenuates Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia

Abstract: Treatment with tolterodine ER in men with BPH and LUTS may be a reasonable therapeutic option as initial therapy or after failed treatment with alpha-blockers.

Cited by 29 publications

References 18 publications

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

How to choose the initial drug treatment for overactive bladder

Efficacy and Safety of Tamsulosin With and Without Flavoxate in the Treatment of Symptomatic Benign Prostastic Hypoplasia: A Randomized, Single-Blind Study

Contact Info

Product

Resources

About